Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 75.01M | 68.59M | 52.51M | 39.97M | 24.66M | 13.79M |
Gross Profit | 58.69M | 55.49M | 42.81M | 32.94M | 19.43M | 10.29M |
EBITDA | 12.30M | 11.90M | 10.38M | 5.25M | 1.12M | 148.12K |
Net Income | 2.84M | 3.00M | 4.55M | 1.21M | -1.95M | -2.17M |
Balance Sheet | ||||||
Total Assets | 244.53M | 207.19M | 118.78M | 106.19M | 72.77M | 64.08M |
Cash, Cash Equivalents and Short-Term Investments | 91.21M | 56.57M | 33.48M | 17.45M | 16.39M | 23.39M |
Total Debt | 784.35K | 608.76K | 541.09K | 882.20K | 792.51K | 987.89K |
Total Liabilities | 64.83M | 62.33M | 36.88M | 30.79M | 17.95M | 13.77M |
Stockholders Equity | 179.70M | 144.86M | 81.91M | 75.40M | 54.82M | 50.31M |
Cash Flow | ||||||
Free Cash Flow | 14.84M | 14.24M | 20.18M | 5.83M | -309.58K | 294.35K |
Operating Cash Flow | 15.73M | 15.13M | 20.47M | 6.12M | -49.97K | 405.14K |
Investing Cash Flow | -28.71M | -31.39M | -4.15M | -21.84M | -10.06M | -9.37M |
Financing Cash Flow | 70.70M | 39.09M | -287.89K | 16.40M | 3.17M | 30.37M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | C$586.89M | 203.18 | 2.15% | ― | 35.97% | -59.04% | |
65 Neutral | C$580.54M | ― | -4.56% | ― | 42.93% | 85.95% | |
55 Neutral | C$10.40M | ― | -244.35% | ― | -71.31% | -53.11% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% | |
24 Underperform | C$19.35M | ― | 366.78% | ― | -35.15% | -6.59% | |
$23.96M | ― | -507.20% | ― | ― | ― | ||
$11.69M | ― | -9999.00% | ― | ― | ― |
VitalHub Corp. announced the results of its annual general meeting, where all director nominees were elected to the board, and MNP LLP was appointed as auditors. The meeting saw a 60.45% participation rate of the total shares issued and outstanding. These developments reinforce VitalHub’s governance structure and ensure continued oversight and financial integrity, which are crucial for its ongoing growth and market positioning.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub has completed the acquisition of Induction Healthcare Group PLC, enhancing its product offerings with Induction’s software solutions like Zesty and Attend Anywhere. This acquisition, valued at approximately £9.7 million, is expected to complement VitalHub’s existing solutions, improve healthcare partner value, and enhance patient outcomes, thereby strengthening its position in the healthcare software industry.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub Corp. has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Alberta, British Columbia, and Ontario. This filing, once finalized, will allow the company to qualify the distribution of up to $250 million in various securities over a 25-month period. Although VitalHub has no immediate plans to offer securities under this prospectus, the move positions the company to quickly capitalize on future opportunities, potentially impacting its financial strategy and market positioning.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub Corp. reported significant financial growth in the first quarter of 2025, with a 54% year-over-year increase in Annual Recurring Revenue (ARR) to $73.7 million and a 42% rise in total revenue to $21.7 million. The company is strengthening its infrastructure and exploring strategic acquisitions, including a potential cash acquisition of UK-based Induction Healthcare Group, expected to close in the third quarter of 2025. This acquisition, along with other opportunities in the pipeline, is anticipated to provide strong synergistic value and enhance VitalHub’s market positioning.
VitalHub Corp. has announced it will release its Q1 2025 financial results on May 8, 2025, followed by a conference call on May 9, 2025. This announcement is part of VitalHub’s ongoing efforts to engage with stakeholders and provide transparency about its financial performance, which could impact its market positioning and investor relations.
VitalHub Corp. has announced a recommended cash acquisition of Induction Healthcare Group PLC, valuing the company at approximately £9.7 million. This strategic move aims to integrate Induction’s Zesty platform with VitalHub’s existing offerings, enhancing product efficiency and user experience. The acquisition is expected to expand VitalHub’s geographic reach and improve patient outcomes across key markets. Induction’s directors have unanimously recommended shareholders to vote in favor of the acquisition, which requires court approval and shareholder agreement.